Provera Tablets 10mg (Medroxyprogesterone Acetate)

Adult dose

1. Secondary Amenorrhea Administer 5 to 10 mg of Medroxyprogesterone Acetate once daily by mouth for 5 to 10 days. The recommended dose to convert the endometrium to an optimal secretory state is 10 mg once daily for 10 days. 2. Functional Uterine Bleeding Administer 5 to 10 mg once daily starting from day 16 or 21 of the menstrual cycle for 5 to 10 days. To convert the endometrium to an optimal secretory state, administer 10 mg starting from day 16 of the cycle. 3. Mild or Moderate Endometriosis Administer 10 mg three times a day for 90 consecutive days starting from day 1 of the menstrual cycle. 4. Combination Therapy with Estrogen Administration 1) This medication is administered to women who have not undergone hysterectomy and are undergoing hormonal (estrogen) replacement therapy as follows: - Cyclic therapy: Start 5 to 10 mg of this medication on either day 1 or day 16 of the cycle and administer for 12 to 14 consecutive days. - Continuous therapy: Administer 2.5 mg or 5 mg of this medication daily alongside estrogen therapy. This regimen will result in the cessation of regular bleeding over the months. 2) After diagnosing menopause, progestin challenge testing is recommended for amenorrheic women who have not undergone hysterectomy. ○ Progestin Challenge Test: Administer 10 mg of this medication daily for 10 days. - Negative test: It is determined that there is no withdrawal bleeding, indicating insufficient estrogen secretion and lack of stimulation of the endometrium. Hormonal replacement therapy combining estrogen and this medication should be considered for these women. - Positive test: Withdrawal bleeding occurs within 7 days after finishing the progestin challenge test, indicating there is sufficient endogenous estrogen to stimulate the endometrium. This medication should be administered until withdrawal bleeding stops. The cessation of withdrawal bleeding indicates that stimulation of the endometrium has ceased due to decreased estrogen secretion. Hormonal replacement therapy combining estrogen and this medication should be considered for these women.

This medication should not be used during the first 4 months of pregnancy as it may increase the risk of fetal genital abnormalities or miscarriage. Potential risks of this medication to the fetus during pregnancy must be fully recognized. Prolonged use may reduce bone density, so adequate intake of calcium and vitamin D is recommended, and bone density tests should be conducted if necessary. Caution should be taken as there may be an increased risk of dementia in women over 65 years. This medication should not be used in patients with certain cardiovascular diseases, liver disease, or a history of cancer, and it should also be avoided in cases of hypersensitivity. Patients with underlying diseases such as thrombosis, hypertension, diabetes, and liver disease should be administered with caution, and any abnormal symptoms should be immediately consulted with a physician. This medication may cause various side effects, so careful observation is required for symptoms such as breast pain, skin rashes, indigestion, and psychiatric symptoms. Regular check-ups should be conducted before and during treatment to monitor health status, particularly breast and pelvic examinations. The use of this medication should be confirmed only after pregnancy status has been established, and pregnancy should be avoided during use. This medication may interact with other drugs, so if any medications are being taken, it is essential to inform the healthcare provider. It is recommended to discontinue breastfeeding if using this medication during lactation. The safety and efficacy in children have not been established, so it should be avoided. In case of overdose, corticosteroid-like effects may occur, so caution is advised. This medication should be stored out of reach of children and it is advisable not to change the container.

Serious side effects

Hives, angioedema, anaphylaxis and anaphylactoid reactions, embolism and thrombosis (venous thromboembolism, myocardial infarction, cerebral thrombosis, cerebral embolism, thrombophlebitis, pulmonary embolism, retinal vascular thrombosis, mesenteric embolism), cerebral hemorrhage, congestive heart failure, jaundice, cholestatic jaundice, dyspnea, optic neuritis (which may cause partial or complete vision loss)

Mild side effects

Breast pain, breast tenderness, watery discharge, itching, generalized rash, acne, erythema multiforme, melasma, liver spots, hirsutism, alopecia, palpitations, tachycardia, increased blood pressure, delayed anovulation, cervical dysplasia, cervical discharge, premenstrual syndrome, changes in libido, symptoms similar to cystitis, functional disorders, irregular/increased/decreased/spotting bleeding, depression, insomnia, nervousness, euphoria, concentration difficulties, apathy, agitation, drowsiness,

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is also best to keep it at a normal indoor temperature, avoiding excessively hot or cold locations.

Appearance

White, biconvex round tablets

Package unit

40 tablets (10 tablets/blister x 4)